Pharmaceuticals

Zynlonta Market Forecast 2026–2035: How to Leverage Market Growth

March 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the zynlonta market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Zynlonta Market’s size between 2026 and 2030?

Historical growth can be linked to a rising occurrence of hematological malignancies, alongside the increasing ineffectiveness of conventional chemotherapy. Additional drivers include the expansion of specialized oncology centers, enhanced diagnostic precision for lymphoma subtypes, and the growing clinical integration of antibody-drug conjugate (ADC) therapies.

The growth observed in the forecast period is primarily driven by several factors, including the accelerated development of next-generation antibody-drug conjugates (ADCs), the rising demand for personalized cancer treatments, the expansion of targeted oncology pipelines, increased investments in biologic cancer drugs, and the greater adoption of combination cancer therapies.

Key trends anticipated during the forecast period encompass the wider adoption of antibody-drug conjugate therapies, a growing utilization of targeted treatments for B-cell lymphomas, an amplified focus on precision oncology drugs, the broadening of hospital-based oncology infusion services, and a heightened emphasis on therapies for relapsed and refractory cancers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20435&type=smp

Which Drivers Are Shaping Strategic Decisions In The Zynlonta Market?

The anticipated increase in clinical trials is projected to boost the future growth of the zynlonta market. These research investigations involve human participants and aim to evaluate the safety, efficacy, and overall effectiveness of medical interventions, which encompass drugs, devices, procedures, and diagnostic tools. Factors contributing to the rise in clinical trials include an escalating demand for new therapeutic options, continuous advancements in medical research, and the imperative to address evolving health challenges. Zynlonta benefits from clinical trials through the generation of compelling clinical evidence, which validates its safety and efficacy, thereby aiding regulatory approvals and fostering increased physician confidence in its therapeutic deployment. For example, data from December 2024, provided by the UK-based Association of the British Pharmaceutical Industry (ABPI), indicated a consecutive annual increase in pharmaceutical industry trials launched within the UK. The number rose from 411 in 2022 to 426 in 2023, reflecting an approximate 9.5% increase in registered trials. Thus, the expansion of clinical trials is a key factor propelling the growth of the zynlonta market.

What Segment Classifications Make Up The Zynlonta Market?

The zynlonta market covered in this report is segmented –

1) By Indication: Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma, DLBCL Arising From Follicular Lymphoma

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Adult Patients, Geriatric Patients

Which Trends Are Guiding The Evolution Of The Zynlonta Market?

A major trend within the zynlonta market is the development of innovative therapies, such as combination approaches, to improve treatment effectiveness and enhance patient outcomes in cancer care. Combination therapies involve the use of two or more treatments, like drugs or other modalities, to increase therapeutic efficacy and target multiple aspects of a disease. For instance, in April 2024, ADC Therapeutics, a Switzerland-based biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for treating hematological malignancies and solid tumors, released updates on their LOTIS-7 clinical trial. This trial evaluates Zynlonta (loncastuximab tesirine-lpyl) when combined with bispecific antibodies such as glofitamab or mosunetuzumab. The study aims to treat heavily pretreated patients suffering from relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Which Leading Companies Dominate The Zynlonta Market Share?

Major companies operating in the zynlonta market are ADC Therapeutics SA, Avid Bioservices Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/zynlonta-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Zynlonta Market?

North America was the largest region in the zynlonta market in 2025. The regions covered in the zynlonta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Zynlonta Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20435&type=smp

Browse Through More Reports Similar to the Global Zynlonta Market 2026, By The Business Research Company

Zinc Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-global-market-report

Zinc Oxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-oxide-global-market-report

Zinc Citrate Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-citrate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795